Cyclooxygenase inhibition attenuates 3-nitropropionic acid-induced neurotoxicity in rats: Possible antioxidant mechanisms

Fundamental and Clinical Pharmacology

Volumn 21, Issue 3, 2007, Pages 297-306

  Kumar, P ^a   Padi, S S V ^a   Naidu, P S ^a   Kumar, A ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

3 nitropropionic acid; Cognitive impairment; Cyclooxygenase inhibitor; Motor activity; Oxidative stress

Indexed keywords

3 NITROPROPIONIC ACID; ANTIOXIDANT; GLUTATHIONE; NAPROXEN; NITRITE; PROSTAGLANDIN SYNTHASE INHIBITOR; SUCCINATE DEHYDROGENASE; VALDECOXIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; LIPID PEROXIDATION; MALE; MOTOR DYSFUNCTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RAT STRAIN; STATISTICAL SIGNIFICANCE; WISTAR RAT;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CYCLOOXYGENASE INHIBITORS; GLUTATHIONE; ISOXAZOLES; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MAZE LEARNING; MEMORY; MOTOR ACTIVITY; NAPROXEN; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; NITRITES; NITRO COMPOUNDS; OXIDATIVE STRESS; PROPIONIC ACIDS; RATS; RATS, WISTAR; SUCCINATE DEHYDROGENASE; SULFONAMIDES;

EID: 34249071895     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2007.00485.x     Document Type: Article

References (44)

1. James L.F., Hartley W.J., Williams M.C., Van Kampen K.R. Field and experimental studies in cattle and sheep poisoned by nitro-bearing astagalus or their toxins. Am. J. Vet. Res. (1980) 41 377 382.
2. Ludolph A.C., He F., Spencer P.S., Hammerstad J., Sabri M. 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can. J. Neurol. Sci. (1991) 18 492 498.
3. Tariq M., Haseeb Khan H.A., Elfaki I., Deeb S.A., Moutaery K.A. Neuroprotective effect of nicotine against 3-nitroprpionic acid-induced experimental Huntington's disease in rats. Brain Res. Bull. (2005) 67 161 167.
4. Hamilton B.F., Gould D.H. Nature and distribution of brain lesions in rats intoxicated with 3-NP a type of hypoxic (energy deficient) brain damage. Acta Neuropathol. (1987) 72 286 297.
5. Biniendra Z., Simmons C., Hussion S., Sikker W. Jr., Ali S.F. Effect of acute exposure to 3-NP on activities of endogenous antioxidants in the rat brain. Neurosci. Lett. (1998) 251 173 176.
6. Alexi T., Borlongan C.V., Faull R.L. et al. Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases. Prog. Neurobiol. (2000) 60 409 470.
7. Gardian G., Vecsei L. Huntington's disease: pathomechanism and therapeutic perspectives. J. Neural. Transm. (2004) 111 1485 1494.
8. Arzberger T., Krampfl K., Leimgruber S., Weindl A. Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease - an in situ hybridization study. J. Neuropathol. Exp. Neurol. (1997) 56 440 454.
9. Hurley S.D., Olschowka J.A., O'Banion M.K. Cyclooxygenase inhibition as a strategy to ameliorate brain injury. J. Neurotrauma (2002) 19 1 15.
10. Miettinen S., Fusco F.R., Yrjanheikki J. et al. Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-d-aspartic acid-receptors and phospholipase A2. Proc. Natl Acad. Sci. U.S.A. (1997) 94 6500 6505.
11. Nogawa S., Zhang F., Ross M.E., Iadecola C. Cyclooxygenase-2 gene expression in neurons contributes to ischemic brain damage. J. Neurosci. (1997) 17 2746 2755.
12. Xiang Z., Ho L., Valdellon J. et al. Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology. Neurobiol. Aging (2002) 23 327 334.
13. Salzberg-Brenhouse H.C., Chen E.Y., Emerich D.F. et al. Inhibitors of cyclooxygenase-2, but not cyclooxygenase-1 provide structural and functional protection against quinolinic acid-induced neurodegeneration. J. Pharmacol. Exp. Ther. (2003) 306 218 228.
14. Silakova J.M., Hewett J.A., Hewett S.J. Naproxen reduces excitotoxic neurodegeneration in vivo with an extended therapeutic window. J. Pharmacol. Exp. Ther. (2004) 309 1060 1066.
15. Dhir A., Naidu P.S., Kulkarni S.K. Protective effect of cyclooxygenase-2 (COX-2) inhibitors but not non-selective cyclooxygenase (COX)-inhibitors on ethanol withdrawal-induced behavioural changes. Addict. Biol. (2005) 10 329 335.
16. Padi S.S.V., Kulkarni S.K. Differential effects of naproxen and rofecoxib on the development of hypersensitivity following nerve injury in rats. Pharmacol. Biochem. Behav. (2004) 79 349 358.
17. Naidu P.S., Singh A., Kulkarni S.K. Quercetin, a bioflavonoid, attenuates haloperidol-induced orofacial dyskinesia. Neuropharmacology (2003) 44 1100 1106.
18. Verma A., Kulkarni S.K. Evaluation of learning and memory mechanisms employing plus maze in rats and mice. Prog. Neuropsychopharmacol. Biol. Psychiat. (1992) 16 117 125.
19. Frautschy S.A., Hu W., Kim P. et al. Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology. Neurobiol. Aging (2001) 22 993 1005.
20. Wills E.D. Mechanism of lipid peroxide formation in animal. Biochem. J. (1966) 99 667 676.
21. Ellman G.L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. (1959) 82 70 77.
22. Green L.C., Wagner D.A., Glogowski J., Skipper P.L., Wishnok J.S., Tannebaum S.R. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Ann. Biochem. (1982) 126 131 138.
23. Gornall A.G., Bardawill C.J., David M.M. Determination of serum proteins by means of the biuret reaction. J. Biol. Chem. (1949) 177 751 766.
24. Hamilton J.M., Wolfson T., Peavy G.M., Jacobson M.W., Corey-Bloom J. Huntington Study Group. Rate and correlates of weight change in Huntington's disease. J. Neurol. Neurosurg. Psychiatry (2004) 75 209 212.
25. Saydoff J.A., Liu L.S., Garcia R.A., Hu Z., Li D., Von Borstel R.W. Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's disease. Brain Res. (2003) 994 44 54.
26. Guyot M.C., Hantraye P., Dolan R., Palfi S., Maziere M., Brouillet E. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. Neuroscience (1997) 79 45 56.
27. Sugino T., Nozaki K., Tokime T., Hashimoto N., Kikuchi H. 3-Nitropropionic acid induces poly (ADP-ribosyl) ation and apoptosis related gene expression in the striatum in vivo. Neurosci. Lett. (1997) 237 121 124.
28. Matsumoto Y., Yamaguchi T., Watanabe S., Yamamoto T. Involvement of arachidonic acid cascade in working memory impairment induced by interleukin-1 beta. Neuropharmacology (2004) 46 1195 2000.
29. Bruce-Keller A.J., Li Y.J., Lovell M.A. et al. 4-Hydroxynonenal, a product of lipid peroxidation, damages cholinergic neurons and impairs visuospatial memory in rats. J. Neuropathol. Exp. Neurol. (1998) 57 257 267.
30. Candelario-Jalil E., Gonzalez-Falcon A., Garcia-Cabrera M. et al. Assessment of the relative contribution of COX-1 and COX-2 isoforms to ischemia-induced oxidative damage and neurodegeneration following transient global cerebral ischemia. J. Neurochem. (2003) 86 545 555.
31. Pepicelli O., Fedele E., Bonanno G. et al. In vivo activation of N-methyl-d-aspartate receptors in the rat hippocampus increases prostaglandin E(2) extracellular levels and triggers lipid peroxidation through cyclooxygenase-mediated mechanisms. J. Neurochem. (2002) 81 1028 1034.
32. Hewett S.J., Uliasz T.F., Vidwans A.S., Hewett J.A. Cyclooxygenase-2 contributes to N-methyl-d-aspartate-mediated neuronal cell death in primary cortical cell culture. J. Pharmacol. Exp. Ther. (2000) 293 417 425.
33. Schilling G., Savonenko A.V., Coonfield M.L., Morton J.L. Environmental, pharmacological and genetic modulation of HD phenotypic in transgenic mice. Exp. Neurol. (2004) 187 137 149.
34. Kukreja R.C., Kontos H.A., Hess M.L., Ellis E.F. PGH synthase and lipooxygenase generate superoxide in the presence of NADH or NADPH. Circ. Res. (1986) 59 612 619.
35. Montilla P., Tunez I., Munoz M.C. et al. Effect of glucocorticoids on 3-nitropropionic acid-induced oxidative stress in synaptosomes. Eur. J. Pharmacol. (2004) 488 19 25.
36. Schulz J.B., Henshaw D.R., MacGarvey U., Beal M.F. Involvement of oxidative stress in 3-nitropropionic acid neurotoxicity. Neurochem. Int. (1996b) 29 167 171.
37. Tunez I., Montilla P., Del Carmen Munoz M., Feijoo M., Salcedo M. Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington's disease. J. Pineal Res. (2004) 37 252 256.
38. Kim G.W., Chan P.H. Involvement of superoxide in excitotoxicity and DNA fragmentation in striatal vulnerability in mice after treatment with the mitochondrial toxin, 3-nitropropionic acid. J. Cereb. Blood Flow Metab. (2002) 22 798 809.
39. Perez-De La Cruz V., Gonzalez-Cortes C., Pedraza-Chaverri J., Maldonado P.D., Andres-Martinez L., Santamaria A. Protective effect of S-allylcysteine on 3-nitropropionic acid-induced lipid peroxidation and mitochondrial dysfunction in rat brain synaptosomes. Brain Res. Bull. (2006) 68 379 383.
40. Teismann P., Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse (2001) 39 167 174.
41. Beal M.F., Ferrante R.J., Henshaw R. et al. 3-Nitropropionic acid neurotoxicity is attenuated in copper/zinc superoxide dismutase transgenic mice. J. Neurochem. (1995) 65 919 922.
42. Fass U., Panickar K., Personett D. et al. Differential vulnerability of primary cultured cholinergic neurons to nitric oxide excess. Neuroreport (2000) 11 931 936.
43. Asanuma M., Nishibayashi-Asanuma S., Miyazaki I., Kohno M., Ogawa N. Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals. J. Neurochem. (2001) 76 1895 1904.
44. Goodwin D.C., Landino L.M., Marnett L.J. Effects of nitric oxide and nitric oxide-derived species on prostaglandin endoperoxide synthase and prostaglandin biosynthesis. FASEB J. (1999) 13 1121 1136.